As part of the French Genomic Medicine Plan 2025 (FGM), the SeqOIA and AURAGEN platforms were selected to perform high-throughput genomic sequencing.
The SONCO (Sequencing Oncology Cohort) project combines their medical and economic evaluations into a single national cohort. Its objective is to assess the impact of genomic sequencing on care pathways and treatment recommendations by collecting indicators related to quality, turnaround time, and patient information. Clinical data are gathered from molecular tumor board reports (via SPICE and HYGEN) and from hospital medical records.
This cohort is intended to support public health decision-making and help anticipate the organization of future genomic platforms.
Patients diagnosed with cancer and referred for high-throughput sequencing
Sequencing pre-indication validated: Patients for whom the pre-indication for sequencing the genome, exome, and RNA has been validated by the upstream RCP (Multidisciplinary Tumor Board) since January 1, 2021.
Opposition to data reuse, unvalidated upstream RCP
Patients diagnosed with cancer and referred for high-throughput sequencing
Case-only
Retrospective
Not listed
Calculation of result turnaround time.
interval from the upstream Multidisciplinary Team (MDT) meeting to the downstream multidisciplinary meeting
Treatment recommendation issued following the downstream multidisciplinary meeting
Prescription details include the actual treatment prescribed, the patient's response to treatment, the number of therapy lines received after the initial prescription, the specific molecule prescribed, and the type of genomic alteration guiding the therapeutic choice.
Sample Arrival Time for Analysis
Interval between the date of the upstream Multidisciplinary Team (MDT) meeting and the date of arrival of the tumor sample at one of the platforms for anatomical pathology prequalification/qualification
Elapsed time from sequencing to the signing of the medical biology report by the biologist
Delay between the date of sequencing and the date the medical biology report is validated by the biologist.
Elapsed time from sequencing to the downstream multidisciplinary meeting.
Delay between the sequencing date and the downstream multidisciplinary meeting
Click on the lead sponsor to view all of their trials.
Assistance Publique - Hôpitaux de Paris
Lead sponsor
AuraGen Aesthetics LLC
Collaborator
Centre Leon Berard
Collaborator
Laboratoire SeqOIA
Collaborator
PLAN FRANCE MÉDECINE GÉNOMIQUE 2025
Collaborator
